Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response

被引:6
|
作者
Gu, Tianwei [1 ]
Hong, Ting [1 ]
Zhang, Pengzi [1 ]
Tang, Sunyinyan [1 ]
Bi, Yan [1 ]
Lu, Hai [2 ]
Men, Lichuang [2 ]
Ma, Dongwei [2 ]
Zhu, Dalong [1 ]
机构
[1] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
[2] Sanofi Investment Co Ltd, Shanghai, Peoples R China
关键词
Asia; Basal insulin; China; Dose titration; Insulin glargine 100 U/mL; Nomogram; Pooled analysis; Type 2 diabetes mellitus; BODY-MASS INDEX; BASAL INSULIN; OBSERVATIONAL REGISTRY; PREMIXED INSULIN; TREATMENT ORBIT; UNITED-STATES; NPH INSULIN; TITRATION; THERAPY; TARGET;
D O I
10.1007/s13300-018-0381-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: In Asia, patients with type 2 diabetes mellitus (T2DM) often have suboptimal glycemic control for many years prior to initiating basal insulin. Active titration of basal insulin is also required to improve glycemic outcomes. This pooled analysis was conducted to determine the impact of patient baseline covariates on the required dose of basal insulin and treatment response, for the improved management of Asian patients with T2DM. Methods: Data on insulin-naive Asian patients with T2DM who initiated and fully titrated insulin glargine 100 U/mL (Gla-100) for >= 20 weeks were pooled from seven randomized, controlled, treat-to-target trials. Covariance and multivariate linear/logistic regression analyses were applied to determine the impact of the baseline covariates on Gla-100 dose (primary outcome) and treatment response (secondary outcomes) at week 24 for patients from Asia (N = 724) and from China alone (n = 249). Based on the multivariate analysis for the primary outcome in the Asian population, a nomogram was developed. Results: The dose of Gla-100 at week 24 was negatively correlated with age and positively correlated with body mass index (BMI) and fasting plasma glucose (FPG) at baseline in both Asian and Chinese populations. In both populations, higher baseline glycated hemoglobin (HbA(1c)) was associated with a lower reduction in HbA1c from baseline, higher HbA(1c) at week 24, and a lower chance of achieving HbA(1c) < 7% at week 24. The constructed nomogram enables calculation of the likely dose of Gla-100 required by Asian patients with T2DM to achieve HbA(1c) < 7% at week 24. Conclusions: Higher doses of Gla-100 are likely to be required in younger patients or patients with higher baseline BMI or FPG. The nomogram developed in this study can aid clinicians to titrate the dose of Gla-100 appropriately. Evidence in this pooled analysis also indicates that initiating basal insulin at a lower HbA(1c) can lead to greater glycemic control.
引用
收藏
页码:771 / 787
页数:17
相关论文
共 50 条
  • [31] Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    DIABETES OBESITY & METABOLISM, 2020, 22 : 3 - 13
  • [32] Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective
    Mezquita-Raya, Pedro
    Darba, Josep
    Ascanio, Meritxell
    Ramirez de Arellano, Antonio
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : 587 - 595
  • [33] Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    Cetinarslan, Berrin
    Cetinkalp, Sevki
    Kaya, Ahmet
    Ersoy, Canan
    Kebapci, Nur
    Comlekci, Abdurrahman
    Tutuncu, Neslihan Bascil
    Deyneli, Oguzhan
    Oguz, Aytekin
    Ilkova, Hasan
    Yilmaz, Temel
    Hekimsoy, Zeliha
    Unubol, Mustafa
    Balci, Mustafa Kemal
    Atmaca, Ayseguel
    Dagdelen, Selcuk
    Yetkin, Ilhan
    Guler, Serdar
    Otunc, Goektuerk
    Ozhan, Leyla
    ENDOCRINOLOGY RESEARCH AND PRACTICE, 2024, 28 (01): : 4 - 11
  • [34] Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs
    Kalra, Sanjay
    Plata-Que, Teresa
    Kumar, Dileep
    Mumtaz, Malik
    Sondergaard, Flemming
    Kozlovski, Plamen
    Bebakar, Wan Mohamad Wan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 88 (03) : 282 - 288
  • [35] Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland
    Braendie, M.
    Azoulay, M.
    Greiner, R. -A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (03) : 217 - 230
  • [36] Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
    Yang, Wenying
    Ersoy, Canan
    Wang, Guixia
    Ye, Shandong
    Liu, Jun
    Miao, Heng
    Asirvatham, Arthur
    Werther, Shanti
    Kadu, Priti
    Chow, Francis
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 158 - 166
  • [37] Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes
    Lin, Shi-Dou
    Tsai, Shih-Tzer
    Tu, Shih-Te
    Su, Ching-Chieh
    Chen, Jung-Fu
    Lu, Chieh-Hsiang
    Wang, Chao-Hung
    Yu, Neng-Chun
    Hsu, Shang-Ren
    Hsieh, Ming-Chia
    PRIMARY CARE DIABETES, 2015, 9 (02) : 135 - 141
  • [38] How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus?
    Marks, Jennifer B.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (09): : 490 - 491
  • [39] Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs
    Ohta, Akio
    Kato, Hiroyuki
    Murayama, Katura
    Hashimoto, Eriko
    Murakami, Mariko
    Nishine, Ami
    Ohshige, Toshihiko
    Sada, Yoshiyuki
    Asai, Shiko
    Kawata, Takehiro
    Nagai, Yoshio
    Katabami, Takuyuki
    Tanaka, Yasushi
    ENDOCRINE JOURNAL, 2014, 61 (01) : 13 - 18
  • [40] COMPARATIVE STUDY OF ORAL ANTIDIABETIC THERAPY AND INSULIN THERAPY ON HEPATIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Hoza, Anica
    Moldovan, Corina
    Farcas, Dorina Maria
    Pallag, Annamaria
    Nemeth, Sebastian
    Marc, Felicia
    FARMACIA, 2018, 66 (04) : 652 - 657